Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis.
Leung-Theung-Long S, Coupet CA, Gouanvic M, Schmitt D, Ray A, Hoffmann C, Schultz H, Tyagi S, Soni H, Converse PJ, Arias L, Kleinpeter P, Sansas B, Mdluli K, Vilaplana C, Cardona PJ, Nuermberger E, Marchand JB, Silvestre N, Inchauspé G. Leung-Theung-Long S, et al. Among authors: sansas b. PLoS One. 2018 May 2;13(5):e0196815. doi: 10.1371/journal.pone.0196815. eCollection 2018. PLoS One. 2018. PMID: 29718990 Free PMC article.
A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model.
Kratzer R, Sansas B, Lélu K, Evlachev A, Schmitt D, Silvestre N, Inchauspé G, Martin P. Kratzer R, et al. Among authors: sansas b. Hum Vaccin Immunother. 2018 Jun 3;14(6):1417-1422. doi: 10.1080/21645515.2018.1433970. Epub 2018 Feb 22. Hum Vaccin Immunother. 2018. PMID: 29388874 Free PMC article.
Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial.
Zoulim F, Fournier C, Habersetzer F, Sprinzl M, Pol S, Coffin CS, Leroy V, Ma M, Wedemeyer H, Lohse AW, Thimme R, Lugardon K, Martin P, Bastien B, Sansas B, Adda N, Halluard C, Bendjama K, Brandely M, Inchauspé G. Zoulim F, et al. Among authors: sansas b. Hum Vaccin Immunother. 2020;16(2):388-399. doi: 10.1080/21645515.2019.1651141. Epub 2019 Oct 4. Hum Vaccin Immunother. 2020. PMID: 31373537 Free PMC article. Clinical Trial.
Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C, Thioudellet C, Hortelano J, Gantzer M, Nourtier V, Claudepierre MC, Sansas B, Préville X, Bendjama K, Quemeneur E, Rittner K. Remy-Ziller C, et al. Among authors: sansas b. Hum Vaccin Immunother. 2018 Jan 2;14(1):140-145. doi: 10.1080/21645515.2017.1373921. Epub 2017 Oct 18. Hum Vaccin Immunother. 2018. PMID: 28925793 Free PMC article.
Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma.
Armand-Labit V, Meyer N, Casanova A, Bonnabau H, Platzer V, Tournier E, Sansas B, Verdun S, Thouvenot B, Hilselberger B, Doncescu A, Lamant L, Lacroix-Triki M, Favre G, Pradines A. Armand-Labit V, et al. Among authors: sansas b. Acta Derm Venereol. 2016 Jan;96(1):29-34. doi: 10.2340/00015555-2156. Acta Derm Venereol. 2016. PMID: 26039581 Free article.